Researchers from the University of Illinois have identified a new inhibitor of the androgen receptor (AR), CPIC, that would be effective in the treatment of Castration Resistant Prostate Cancer (CRPC). CPIC targets a novel site on the full-length and truncated forms of the AR, present in the CRPC. Initial in vivo data has demonstrated that this new class of compounds is capable of inhibiting growth of prostate cancer cells. Furthermore, CPIC has shown to be 40x more potent against the truncated AR compared to current small molecules against the truncated AR.